A study of 3,231 Finnish adults tracked over a decade found that people with highly irregular bedtimes faced roughly twice the risk of heart attack or stroke — but only if they also slept less than eight hours. Wake-up time variability showed no link to cardiac events.
A randomized trial of 78 early-morning shift workers found that solriamfetol significantly improved alertness, work performance, and daily functioning — the first time any treatment has been tested for this common but overlooked form of shift work disorder.
A 2024 laboratory study found undisclosed pharmaceuticals, an herbicide, and industrial chemicals in commercially sold melatonin vapes. One device appeared to contain no melatonin at all. Federal regulators have known this product category exists for years. No enforcement action has been taken against any of the major brands currently on the market.
Most headlines focused on the frightening odds ratios. But researchers studying the Parkinson's–sleep disorder connection say the more important finding is this: if you have REM sleep behavior disorder, you likely have years before Parkinson's symptoms appear — and that window may soon be treatable.
A prospective study of 85,618 UK Biobank participants finds that people who naturally rebound after short sleep have lower mortality risk than those who do not — and that severe restriction without recovery raises death risk by up to 38%.
Eli Lilly's agreement to acquire Centessa Pharmaceuticals for up to $7.8 billion marks the largest deal yet in the race to develop orexin agonists — a new class of drugs that could replace or supplement current narcolepsy treatments by restoring the brain's natural wakefulness signals.
A Mass General Brigham study tracking 1,338 older adults for up to 19 years found that frequent napping, particularly in the morning, was associated with significantly higher mortality risk.